223 related articles for article (PubMed ID: 29175457)
41. Theranostic imaging of liver cancer using targeted optical/MRI dual-modal probes.
Chen Q; Shang W; Zeng C; Wang K; Liang X; Chi C; Liang X; Yang J; Fang C; Tian J
Oncotarget; 2017 May; 8(20):32741-32751. PubMed ID: 28416757
[TBL] [Abstract][Full Text] [Related]
42. Co-loaded paclitaxel/rapamycin liposomes: Development, characterization and in vitro and in vivo evaluation for breast cancer therapy.
Eloy JO; Petrilli R; Topan JF; Antonio HMR; Barcellos JPA; Chesca DL; Serafini LN; Tiezzi DG; Lee RJ; Marchetti JM
Colloids Surf B Biointerfaces; 2016 May; 141():74-82. PubMed ID: 26836480
[TBL] [Abstract][Full Text] [Related]
43. Nuclear and Fluorescent Labeled PD-1-Liposome-DOX-
Du Y; Liang X; Li Y; Sun T; Jin Z; Xue H; Tian J
Mol Pharm; 2017 Nov; 14(11):3978-3986. PubMed ID: 29016143
[TBL] [Abstract][Full Text] [Related]
44. Tumor Microenvironmental pH and Enzyme Dual Responsive Polymer-Liposomes for Synergistic Treatment of Cancer Immuno-Chemotherapy.
Liu Y; Chen XG; Yang PP; Qiao ZY; Wang H
Biomacromolecules; 2019 Feb; 20(2):882-892. PubMed ID: 30621390
[TBL] [Abstract][Full Text] [Related]
45. Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model.
Kim KJ; Kim JH; Lee SJ; Lee EJ; Shin EC; Seong J
Oncotarget; 2017 Jun; 8(25):41242-41255. PubMed ID: 28465485
[TBL] [Abstract][Full Text] [Related]
46. Second near-infrared photothermal-amplified immunotherapy using photoactivatable composite nanostimulators.
Sun H; Yu T; Li X; Lei Y; Li J; Wang X; Peng P; Ni D; Wang X; Luo Y
J Nanobiotechnology; 2021 Dec; 19(1):433. PubMed ID: 34930269
[TBL] [Abstract][Full Text] [Related]
47. Carboplatin and programmed death-ligand 1 blockade synergistically produce a similar antitumor effect to carboplatin alone in murine ID8 ovarian cancer model.
Zhu X; Xu J; Cai H; Lang J
J Obstet Gynaecol Res; 2018 Feb; 44(2):303-311. PubMed ID: 29171115
[TBL] [Abstract][Full Text] [Related]
48. Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma.
Hermel DJ; Ott PA
Cancer Metastasis Rev; 2017 Mar; 36(1):43-50. PubMed ID: 28181070
[TBL] [Abstract][Full Text] [Related]
49. Sorafenib and gadolinium co-loaded liposomes for drug delivery and MRI-guided HCC treatment.
Xiao Y; Liu Y; Yang S; Zhang B; Wang T; Jiang D; Zhang J; Yu D; Zhang N
Colloids Surf B Biointerfaces; 2016 May; 141():83-92. PubMed ID: 26844644
[TBL] [Abstract][Full Text] [Related]
50. Stabilized liposomal nanohybrid cerasomes for drug delivery applications.
Cao Z; Ma Y; Yue X; Li S; Dai Z; Kikuchi J
Chem Commun (Camb); 2010 Aug; 46(29):5265-7. PubMed ID: 20411203
[TBL] [Abstract][Full Text] [Related]
51. Targeted MRI and chemotherapy of ovarian cancer with clinic available nano-drug based nanoprobe.
Dong L; Zhang X; Cai L; Zuo F; Zhao M; Wang Q; Zhang S; Xu K; Li J
Biomed Pharmacother; 2020 Oct; 130():110585. PubMed ID: 32771892
[TBL] [Abstract][Full Text] [Related]
52. Intrinsically Mn2+-Chelated Polydopamine Nanoparticles for Simultaneous Magnetic Resonance Imaging and Photothermal Ablation of Cancer Cells.
Miao ZH; Wang H; Yang H; Li ZL; Zhen L; Xu CY
ACS Appl Mater Interfaces; 2015 Aug; 7(31):16946-52. PubMed ID: 26196160
[TBL] [Abstract][Full Text] [Related]
53. Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy.
Sonpavde G; Pond GR; Mullane S; Ramirez AA; Vogelzang NJ; Necchi A; Powles T; Bellmunt J
BJU Int; 2017 Apr; 119(4):579-584. PubMed ID: 27700015
[TBL] [Abstract][Full Text] [Related]
54. IGF1 Receptor Targeted Theranostic Nanoparticles for Targeted and Image-Guided Therapy of Pancreatic Cancer.
Zhou H; Qian W; Uckun FM; Wang L; Wang YA; Chen H; Kooby D; Yu Q; Lipowska M; Staley CA; Mao H; Yang L
ACS Nano; 2015 Aug; 9(8):7976-91. PubMed ID: 26242412
[TBL] [Abstract][Full Text] [Related]
55. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ
Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346
[TBL] [Abstract][Full Text] [Related]
56. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
[TBL] [Abstract][Full Text] [Related]
57. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
58. Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors.
Tanoue K; Rosewell Shaw A; Watanabe N; Porter C; Rana B; Gottschalk S; Brenner M; Suzuki M
Cancer Res; 2017 Apr; 77(8):2040-2051. PubMed ID: 28235763
[TBL] [Abstract][Full Text] [Related]
59. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
[TBL] [Abstract][Full Text] [Related]
60. Peptide-based PET quantifies target engagement of PD-L1 therapeutics.
Kumar D; Lisok A; Dahmane E; McCoy M; Shelake S; Chatterjee S; Allaj V; Sysa-Shah P; Wharram B; Lesniak WG; Tully E; Gabrielson E; Jaffee EM; Poirier JT; Rudin CM; Gobburu JV; Pomper MG; Nimmagadda S
J Clin Invest; 2019 Feb; 129(2):616-630. PubMed ID: 30457978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
